European Atherosclerosis Society

Hot off the press 🔥 The #EAS2025 abstracts have just been published in Atherosclerosis! Check out the cutting-edge research shaping the future of lipid & cardiovascular science 👉 atherosclerosis-journal.com/issue/S0021-91… 🌟 #EASSoMe @society_eas

We just published our multispecialty view on adherence @MeralKayikcoglu @DrMarthaGulati @TKDsosyal @ProfKausikRay @rauldsf_santos @drpablocorral frontiersin.org/journals/pharm…

I recently shared how I witnessed my dad's heart attack, so life's been stressful. He is doing well & I had a busy but fun hospital call week rounding with #trainees. Teaching & laughing with them them is by far fav part of my job! Plus I can be in🤓 mode & scruffy 😂 #funshare

💉Targeting Triglycerides: The Future is Here 👉From ApoCIII to ANGPTL3 and FGF-21 analogues, new siRNA and ASO therapies are transforming the landscape of hypertriglyceridemia management. 📉 TG reductions reaching up to 80%! 👉Mild to severe HTG, monogenic or multifactorial —…

👉  New Evidence: Lifetime Risk Starts Early 👆 A 22-year follow-up of young adults from the CARDIA study shows that cumulative exposure to apoB, LDL-P, and TRL-P between ages 18–40 significantly increases the risk of ASCVD events later in life. 📈 Each 1 SD increase in these…

Only 1 in 3 Italian secondary‑prevention pts hit LDL‑C < 55 mg/dL in the #BRINGUP registry (n = 4 790). At discharge Statin + ezetimibe  74 %, but PCSK9/i use still low. Big room for more intensive therapy! #CardioTwitter #lipids internationaljournalofcardiology.com/article/S0167-…

It was great to record an #AtheroTalk podcast and talk about our research and establishing the startup company moncytehealth.com! A big thank you to the team, especially Sanne M. and @azinkh96 for interviewing me and doing the recording. It has been a very nice experience!

We’re excited to launch three new expert-led Short Track Courses, designed to equip healthcare professionals with focused, up-to-date knowledge in key areas of lipidology and cardiovascular prevention: eas.to/ShortTracks. 🔶 Novel Approaches to Lipid Lowering Therapies 🔶…

New editorial in @ATHjournal highlights our latest work! Using an AI-driven method to extract aortic diameters from EHRs, we uncover sex-specific responses to antiplatelet therapy. Read more: atherosclerosis-journal.com/article/S0021-…

New #AtheroTalk! Prof. Noam Zelcer on lipid metabolism, failure as a feature of science, and why go/no-go milestones matter in research. Spotify: eas.to/ATHTalkE13S Apple: eas.to/ATHTalkE13A YouTube: eas.to/ATHTalkE13Y #LipidResearch #Cardiometabolic #EAS

☝️Just published our review on SGLT2 inhibitors and atherosclerosis. Grateful to my co-authors for their valuable contributions! 🔗 Read the full article here: doi.org/10.1016/j.ajpc… @maciejbanach @cardioceptor @balta_anastasia @ziya_sener @fotisbarkas @society_eas

It was a pleasure presenting our work on the pathophysiology of Lp(a) in ASCVD and AVS at #ISFA2025 in Bangkok. What a great conference with fantastic colleagues it was!

🚨Latest piece from #Saeedi_Lab is out in @NatRevCardiol. This article highlights the need for looking beyond gut #microbiome composition to focus on its #metabolites as modifiable #cardiovascular & #aging risk factors. @CTECresearch @Unispital_USZ @CardioZurich @FrancescoPaneni

In episode 13, we talk with Prof. Noam Zelcer, a globally respected expert in the field of molecular regulation of lipid metabolism and cardiometabolic diseases. He shares his perspectives on the evolving field of lipid metabolism research. Besides his scientific insights, he…

I am presenting at #ASPC2025 on August 1st in Boston, US. If you are attending the event, let us meet , I shall be present at IAS booth there with my colleague Michelle Winkour @atherosociety @SamiaMoraMD @society_eas @ASPCardio

Our #metanalysis published, led by Dr. Mousavi & Dr. Hosseini in #AmericanJournalCardiology. It demonstrated the efficacy of #DOACs as first-line treatment for patients diagnosed with cancer associated thrombosis. #CardioOnc

💓 Heart rate lowering: friend or foe? Slowing heart rate can reduce myocardial oxygen demand—but go too far, and you risk impairing coronary perfusion, worsening heart failure, or increasing mortality in select groups. A double-edged sword: benefit depends on baseline risk,…

Have you checked out the latest #AtheroTalk episode yet? 🎙️ It’s out now and worth a listen! @society_eas #academic #podcast 🎧 Spotify: open.spotify.com/episode/5X2j1X…

Alexander Lyons summarizes the EAS-LIPRA project in a short video, highlighting its mission, objectives, and the collaborative spirit behind it. EAS-LIPRA has brought together investigators from multiple African countries with support from various regions of the Western world…